Document is current
Any future updates will be listed below
-
Authors
Brauer, Veronica Soares https://orcid.org/0000-0001-5279-3207
Takemura, Kathryn
Rosati, Barbara
Cavalcanti-Neto, Marinaldo Pacífico
Dasilva, Deveney
Singh, Neelu
Normile, Tyler
Vaccaro, Gabriella
Caso, Giuseppe
Singh, Harpreet
Chen, Bo https://orcid.org/0000-0002-9263-5171
Ojima, Iwao https://orcid.org/0000-0002-3628-1161
McKinnon, David
Del Poeta, Maurizio https://orcid.org/0000-0001-8418-3120
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI125770)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI184929)
U.S. Department of Veterans Affairs (I01BX002624)
U.S. Department of Veterans Affairs (IK6BX005386)
- License Information
-
More Information
Article History
Received: 12 March 2026
Accepted: 5 May 2026
First Online: 28 May 2026
Competing interests
: Dr. Maurizio Del Poeta, M.D., is a Co-Founder and Chief Scientific Officer (CSO) of MicroRid Technologies Inc. whose goal is to develop new anti-fungal agents of therapeutic use. All other authors declare no competing interests.
